CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies
One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (<i>Enterococcus</i>...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/10/7/756 |
| _version_ | 1797529197966524416 |
|---|---|
| author | Manuel González de Aledo Mónica González-Bardanca Lucía Blasco Olga Pacios Inés Bleriot Laura Fernández-García Melisa Fernández-Quejo María López Germán Bou María Tomás |
| author_facet | Manuel González de Aledo Mónica González-Bardanca Lucía Blasco Olga Pacios Inés Bleriot Laura Fernández-García Melisa Fernández-Quejo María López Germán Bou María Tomás |
| author_sort | Manuel González de Aledo |
| collection | DOAJ |
| description | One of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (<i>Enterococcus</i> spp., <i>Staphylococcus aureus</i>, <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i> and <i>Enterobacter</i> spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function. |
| first_indexed | 2024-03-10T10:10:21Z |
| format | Article |
| id | doaj.art-0db6dd7665e0468e9cef6392769c5cd1 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-10T10:10:21Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-0db6dd7665e0468e9cef6392769c5cd12023-11-22T01:12:45ZengMDPI AGAntibiotics2079-63822021-06-0110775610.3390/antibiotics10070756CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical StudiesManuel González de Aledo0Mónica González-Bardanca1Lucía Blasco2Olga Pacios3Inés Bleriot4Laura Fernández-García5Melisa Fernández-Quejo6María López7Germán Bou8María Tomás9Microbiology Department—A Coruña University Hospital (CHUAC), 15006 A Coruña, SpainMicrobiology Department—A Coruña University Hospital (CHUAC), 15006 A Coruña, SpainA Coruña Biomedical Research Institute (INIBIC), University of A Coruña (UDC), 15006 A Coruña, SpainA Coruña Biomedical Research Institute (INIBIC), University of A Coruña (UDC), 15006 A Coruña, SpainA Coruña Biomedical Research Institute (INIBIC), University of A Coruña (UDC), 15006 A Coruña, SpainA Coruña Biomedical Research Institute (INIBIC), University of A Coruña (UDC), 15006 A Coruña, SpainMicrobiology Department—A Coruña University Hospital (CHUAC), 15006 A Coruña, SpainA Coruña Biomedical Research Institute (INIBIC), University of A Coruña (UDC), 15006 A Coruña, SpainMicrobiology Department—A Coruña University Hospital (CHUAC), 15006 A Coruña, SpainMicrobiology Department—A Coruña University Hospital (CHUAC), 15006 A Coruña, SpainOne of the biggest threats we face globally is the emergence of antimicrobial-resistant (AMR) bacteria, which runs in parallel with the lack in the development of new antimicrobials. Among these AMR bacteria pathogens belonging to the ESKAPE group can be highlighted (<i>Enterococcus</i> spp., <i>Staphylococcus aureus</i>, <i>Klebsiella pneumoniae</i>, <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i> and <i>Enterobacter</i> spp.) due to their profile of drug resistance and virulence. Therefore, innovative lines of treatment must be developed for these bacteria. In this review, we summarize the different strategies for the treatment and study of molecular mechanisms of AMR in the ESKAPE pathogens based on the clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins’ technologies: loss of plasmid or cellular viability, random mutation or gene deletion as well directed mutations that lead to a gene’s loss of function.https://www.mdpi.com/2079-6382/10/7/756CRISPR-CasESKAPE pathogenstreatment |
| spellingShingle | Manuel González de Aledo Mónica González-Bardanca Lucía Blasco Olga Pacios Inés Bleriot Laura Fernández-García Melisa Fernández-Quejo María López Germán Bou María Tomás CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies Antibiotics CRISPR-Cas ESKAPE pathogens treatment |
| title | CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies |
| title_full | CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies |
| title_fullStr | CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies |
| title_full_unstemmed | CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies |
| title_short | CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies |
| title_sort | crispr cas a revolution in the treatment and study of eskape infections pre clinical studies |
| topic | CRISPR-Cas ESKAPE pathogens treatment |
| url | https://www.mdpi.com/2079-6382/10/7/756 |
| work_keys_str_mv | AT manuelgonzalezdealedo crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT monicagonzalezbardanca crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT luciablasco crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT olgapacios crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT inesbleriot crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT laurafernandezgarcia crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT melisafernandezquejo crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT marialopez crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT germanbou crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies AT mariatomas crisprcasarevolutioninthetreatmentandstudyofeskapeinfectionspreclinicalstudies |